Background: Hepatitis C virus (HCV) infection is a common cause of acute and chronic hepatitis among the hemodialysis population. To prevent cross infection between hemodialysis patients during the hemodialysis procedure, routine screening of anti-HCV antibody is recommended. However, a reactive anti-HCV EIA test is not equal to active HCV infection. An expensive RT-PCR study is required to confirm HCV viremia. This will significantly increase the cost burden because payment for each hemodialysis treatment is very low in Taiwan. Thus, it is useful to identify parameters that could predict HCV viremia among anti-HCV-reactive patients. In this study, we examined the usefulness of signal-to-cut (S/CO) ratio of anti-HCV antibody in discriminating HCV viremia from non-viremia among the anti-HCV-reactive hemodialysis population. Materials and Methods: In a cross-sectional measurement of anti-HCV antibody among 369 chronic hemodialysis patients, 44 showed reactive and 9 grey zone reaction for anti-HCV. These 53 patients underwent further blood tests for the measurement of AST, ALT and HCV RNA (by RT-PCR). The results of RT-PCR were used as a dependent variable. Then, S/CO ratios of anti-HCV, serum AST, ALT levels, age and duration of hemodialysis were used as independent variables to undergo ROC curve and logistic regression analysis. Results: Thirty-six of the 53 reactive and grey zone patients were positive for HCV RNA in the RT-PCR study. Patients who were positive for HCV RNA had a higher S/CO ratio (p < 0.01), higher AST and ALT levels (p < 0.01), and longer duration on hemodialysis (p < 0.05) than those negative for HCV RNA. Logistic regression revealed that only S/CO ratio was a significant predictor for HCV viremia (p = 0.004). ROC curve analysis showed that S/CO ratio had a highest area under curve (0.967, p < 0.001), followed by ALT (0.826, p < 0.001), AST (0.778, p = 0.001), duration on hemodialysis (0.606, p = 0.215) and age (0.426, p = 0.386) in discriminating HCV viremia from non-viremia. Using a cutoff S/CO ratio of 65, we can confirm HCV viremia with a diagnostic specificity of 100%, sensitivity of 80.1% and positive predictive value of 100%. Conclusion: S/CO ratio is a useful indicator in predicting HCV viremia among anti-HCV-reactive hemodialysis patients. Patients with an S/CO ratio >65 can be regarded as those with active HCV infection. Alternatively, patients with reactive anti-HCV but with an S/CO ratio <65 should receive further RT-PCR test.

Keywords:
S/CO ratio, Anti-HCV antibody, HCV RNA, Reverse transcriptase polymerase chain reaction
1.
Appel N, Schaller T, Penin F, Bartenschlager R: From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem 2006;281:9833-9836.
2.
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for disease control and prevention. MMWR Recomm Rep 1998;47:1-39.
3.
Alavian SM: A shield against a monster: hepatitis C in hemodialysis patients. World J Gastroenterol 2009;15:641-646.
4.
Su Y, Norris JL, Zang C, Peng Z, Wang N: Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis. Hemodial Int 2013;17:532-541.
5.
Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
6.
Tokars JI, Finelli L, Alter MJ, Arduino MJ: National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial 2004;17:310-319.
7.
Mbaeyi C, Thompson ND: Hepatitis C virus screening and management of seroconversions in hemodialysis facilities. Semin Dial 2013;26:439-446.
8.
Yu YC, Wang Y, He CL, Wang MR, Wang YM: Management of hepatitis C virus infection in hemodialysis patients. World J Hepatol 2014;6:419-425.
9.
Afdhal NH: The natural history of hepatitis C. Semin Liver Dis 2004;24(suppl 2):3-8.
10.
Fabrizi F, Poordad FF, Martin P: Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002;36:3-10.
11.
Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P: The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007;14:697-703.
12.
Santos MA, Souto FJ: Infection by the hepatitis C virus in chronic renal failure patients undergoing hemodialysis in Mato Grosso state, central Brazil: a cohort study. BMC Public Health 2007;7:32.
13.
Yeh CN, Lee WC, Chen MF: Hepatic resection for hepatocellular carcinoma in end-stage renal disease patients: two decades of experience at Chang Gung memorial hospital. World J Gastroenterol 2005;11:2067-2071.
14.
Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001;50:1-43.
15.
Rahnavardi M, Hosseini Moghaddam SM, Alavian SM: Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol 2008;28:628-640.
16.
Rigopoulou EI, Stefanidis I, Liaskos C, Zervou EK, Rizos C, Mina P, Zachou K, Syrganis C, Patsidis E, Kyriakopoulos G, Sdrakas L, Tsianas N, Dalekos GN: HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece. J Clin Virol 2005;34:81-85.
17.
da Silva NM, Germano FN, Mendoza-Sassi RA, Seuánez HN, Soares MA, de Martinez AM: Evidence of association between hepatitis C virus genotype 2b and nosocomial transmissions in hemodialysis centers from southern Brazil. Virol J 2013;10:167.
18.
Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, Luma HN, Charlton M: The changing epidemiology of hepatitis C virus infection in the United States: national health and nutrition examination survey 2001 through 2010. J Hepatol 2014;60:691-698.
19.
Doblali T, Bahadi A, El Amrani M, Benyahia M: Prevalence and risk factors of hepatitis C virus infection in patients on hemodialysis: results of a Moroccan study. Med Sante Trop 2014;24:375-378.
20.
Aguirre Valadez J, García Juárez I, Rincón Pedrero R, Torre A: Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review. Ther Clin Risk Manag 2015;11:329-338.
21.
Vallet-Pichard A, Pol S: Hepatitis C virus infection in hemodialysis patients. Clin Res Hepatol Gastroenterol 2013;37:340-346.
22.
Bouzgarrou N, Fodha I, Othman SB, Achour A, Grattard F, Trabelsi A, Pozzetto B: Evaluation of a total core antigen assay for the diagnosis of hepatitis C virus infection in hemodialysis patients. J Med Virol 2005;77:502-508.
23.
Alter MJ, Kuhnert WL, Finelli L: Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for disease control and prevention. MMWR Recomm Rep 2003;52:1-13, 15; quiz CE1-CE14.
24.
Bossi V, Galli C: Quantitative signal of anti-HCV by an automated assay predicts viremia in a population at high prevalence of hepatitis C virus infection. J Clin Virol 2004;30:45-49.
25.
Chiquete E, Sánchez LV, Maldonado M, Quezada D, Panduro A: Prediction of the hepatitis C viremia using immunoassay data and clinical expertise. Ann Hepatol 2005;4:107-114.
26.
Kiely P, Kay D, Parker S, Piscitelli L: The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays. Transfusion 2004;44:349-358.
27.
Sookoian S, Castaño G: Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies. Ann Hepatol 2002;1:179-182.
28.
Huang WS, Lu SN, Wang JH, Lee CM, Tung HD, Chen TM, ChangChien CS: Prediction of viremia for cases of hepatitis C virus (HCV) infection using a third-generation anti-HCV enzyme immunoassay test. Hepatogastroenterology 2005;52:893-896.
29.
Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, Gutekunst K, Rosenstraus M: Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000;38:4171-4179.
30.
Carneiro MA, Martins RM, Teles SA, Silva SA, Lopes CL, Cardoso DD, Vanderborght BO, Yoshida CF: Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: a survey by polymerase chain reaction and serological methods. Mem Inst Oswaldo Cruz 2001;96:765-769.
31.
Balk M, Saydam G, Cengiz D, Türkmen A, Şimşek H, Himmetoğlu T: The utility of ANTI-HCV S/CO ratio, HCV-RNA and ALT test in predicting viremia in ANTI-HCV positive patients. Turk J Biochem 2007;32:51-54.
32.
Dufour DR, Talastas M, Fernandez MD, Harris B, Strader DB, Seeff LB: Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection. Clin Chem 2003;49:479-486.
33.
Thakral B, Marwaha N, Chawla YK, Saluja K, Sharma A, Sharma RR, Minz RW, Agnihotri SK: Prevalence & significance of hepatitis C virus (HCV) seropositivity in blood donors. Indian J Med Res 2006;124:431-438.
34.
Payan C, Raimbert A, Fouchard-Hubert I, Kouyoumdjian S, Lunel-Fabiani F: Quantitative antibody analysis: use for the diagnosis of hepatitis C virus chronic infection. Ann Biol Clin (Paris) 2003;61:311-317.
35.
Moretti M, Pieretti B, Masucci A, Sisti D, Rocchi M, Delprete E: Role of signal-to-cutoff ratios in hepatitis C virus antibody detection. Clin Vaccine Immunol 2012;19:1329-1331.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.